Friday, July 10, 2026
🇺🇸 FDA

pharma · Diphtheria · Diabetes Mellitus, Type 2

Sanofi Pasteur MSD

Sanofi Pasteur

Sanofi Pasteur MSD drug portfolio — 66 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
France, LYON HQ
363 Employees
EMA registrant Type
Company details
Status
Public
HQ
France, LYON
Employees
363
Programs
83
Drugs
66
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Drug Pipeline

Sanofi Pasteur MSD pipeline

Portfolio lens on 66 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Sanofi Pasteur MSD drug portfolio — 66 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

66 compounds

  1. alglucosidase

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Molecular target: Starch.

    Target
    Starch
    Mechanism
    Starch hydrolytic enzyme

  2. alglucosidase alfa

    Alimentary tract and metabolism (A16)

    US regulatory status: approved. Molecular target: Starch.

    Target
    Starch
    Mechanism
    Starch hydrolytic enzyme

  3. alirocumab

    Cardiovascular system (C10)

    US regulatory status: approved. Molecular target: Proprotein convertase subtilisin/kexin type 9.

    Target
    Proprotein convertase subtilisin/kexin type 9
    Mechanism
    Subtilisin/kexin type 9 inhibitor

  4. amcenestrant

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha degrader

  5. anti-

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  6. cabazitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  7. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  8. chimeric

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  9. cholera vaccine, oral, live

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in Sanofi Pasteur MSD's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  10. diethylpropion hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.

    Target
    Sodium-dependent dopamine transporter
    Mechanism
    Norepinephrine transporter inhibitor

  12. docetaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  13. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Sanofi Pasteur MSD's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  14. dupilumab

    Dermatologicals (D11)

    US regulatory status: approved. Molecular target: Interleukin-4 receptor subunit alpha.

    Target
    Interleukin-4 receptor subunit alpha
    Mechanism
    Interleukin-4 receptor subunit alpha antagonist

  15. efmoroctocog alfa

    Blood and blood forming organs (B02)

    Blood and blood forming organs (B02) compound in Sanofi Pasteur MSD's portfolio. Molecular target: Coagulation factor VIII.

    Target
    Coagulation factor VIII
    Mechanism
    Coagulation factor VIII exogenous protein

  16. enoxaparin

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  17. enoxaparin sodium

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Antithrombin-III.

    Target
    Antithrombin-III
    Mechanism
    Antithrombin-III activator

  18. enteric-coated

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  19. fexofenadine

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  21. glargine

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  22. group

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  23. hema-

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  24. hexachlorophene

    US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.

    Target
    Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
    Mechanism
    Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor

  25. human heterologous liver cells

    Alimentary tract and metabolism (A16)

    Alimentary tract and metabolism (A16) compound in Sanofi Pasteur MSD's portfolio.

  26. hydroxychloroquine

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Mechanism: Toll-like receptor 7 antagonist.

    Mechanism
    Toll-like receptor 7 antagonist

  27. inactivated

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  28. inhibitor

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  29. inhibitors

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  30. injection

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  31. insulin

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  32. insulin glargine

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  33. insulin glulisine

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in Sanofi Pasteur MSD's portfolio. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  34. isatuximab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Sanofi Pasteur MSD's portfolio. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  35. japanese encephalitis vaccine (inactivated, adsorbed)

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in Sanofi Pasteur MSD's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  36. leflunomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydroorotate dehydrogenase (quinone), mitochondrial.

    Target
    Dihydroorotate dehydrogenase (quinone), mitochondrial
    Mechanism
    Dihydroorotate dehydrogenase inhibitor

  37. lixisenatide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  38. low-dose

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  39. malignant

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  40. meningococcal

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  43. octocog alfa

    Blood and blood forming organs (B02)

    Blood and blood forming organs (B02) compound in Sanofi Pasteur MSD's portfolio. Molecular target: Coagulation factor VIII.

    Target
    Coagulation factor VIII
    Mechanism
    Coagulation factor VIII exogenous protein

  44. oxaliplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  45. placebo

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  46. pneumococcal

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  47. polysaccharide

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  48. powder

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  49. pseudoephedrine

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Mechanism: Norepinephrine transporter releasing agent.

    Mechanism
    Norepinephrine transporter releasing agent

  51. ramipril

    US regulatory status: approved. Molecular target: Angiotensin-converting enzyme.

    Target
    Angiotensin-converting enzyme
    Mechanism
    Angiotensin-converting enzyme inhibitor

  52. recombinant

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  53. rimonabant

    Alimentary tract and metabolism (A08)

    Alimentary tract and metabolism (A08) compound in Sanofi Pasteur MSD's portfolio. Molecular target: Cannabinoid receptor 1.

    Target
    Cannabinoid receptor 1
    Mechanism
    Cannabinoid CB1 receptor antagonist

  54. risedronate

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  55. risedronate sodium

    US regulatory status: approved. Molecular target: Farnesyl pyrophosphate synthase.

    Target
    Farnesyl pyrophosphate synthase
    Mechanism
    Farnesyl diphosphate synthase inhibitor

  56. saline

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  57. sar443122

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  58. sarilumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.

    Target
    Interleukin-6 receptor subunit alpha
    Mechanism
    Interleukin-6 receptor alpha subunit antagonist

  59. semuloparin sodium

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Molecular target: Antithrombin-III.

    Target
    Antithrombin-III
    Mechanism
    Antithrombin-III inhibitor

  60. sevelamer

    Various (V03)

    Various (V03) compound in Sanofi Pasteur MSD's portfolio.

  61. solution

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  62. solvent

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  63. teplizumab

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in Sanofi Pasteur MSD's portfolio. Molecular target: T-cell surface glycoprotein CD3 epsilon chain.

    Target
    T-cell surface glycoprotein CD3 epsilon chain
    Mechanism
    T-cell surface glycoprotein CD3 epsilon chain other

  64. tolebrutinib

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  65. vaccine

    Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.

  66. vandetanib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Ephrin receptor.

    Target
    Ephrin receptor
    Mechanism
    Ephrin receptor inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.